Mosaiques Diagnostics
Mosaiques Diagnostics specializes in proteomic analysis to scan the body at a molecular level, providing benefits for managing chronic diseases including cancer. They utilize proteome analysis for early disease detection and personalized medicine, marking a significant advancement in biomarker discovery and clinical diagnostics. The company is a leader in clinical proteome analysis, with over 400 scientific publications and collaborations with over 85 universities and research institutes worldwide. They develop diagnostic peptide patterns from body fluids like urine and bile for early and differential detection of diseases such as kidney diseases, cardiovascular diseases, cancer, and graft-versus-host disease, aiming to improve patient care and enable personalized medicine.
Industries
Nr. of Employees
small (1-50)
Mosaiques Diagnostics
Rotenburger Str. 20, D-30659 Hannover, Germany
Patents
Method and device for the qualitative and/or quantitative determination of a protein and/or peptide pattern of a fluid sample, which has been taken from a human or animal body
US-7955862-B2
View Details
Method and device for the qualitative and/or quantitative determination of a protein and/or peptide pattern of a fluid sample, which has been taken from a human or animal body
US-7955862-B2
View DetailsProducts
Curated urinary proteome/peptidome reference resource
A curated repository of endogenous urinary peptides and proteins to support peptide identification, classifier development and cross-study comparisons.
Validated urinary peptide-based diagnostic classifiers
A set of validated urine (and other biofluid) peptide-based classifiers for multiple clinical indications (including chronic kidney disease, graft rejection/GvHD, bladder and prostate cancer, cholangiocarcinoma and acute conditions such as severe COVID-19), developed and evaluated in multicentre cohorts.
Urine-based laboratory diagnostic assays (IVD channel)
Laboratory-implemented urine-based diagnostic tests marketed through diagnostic distribution channels to enable clinical detection and monitoring for selected indications.
Curated urinary proteome/peptidome reference resource
A curated repository of endogenous urinary peptides and proteins to support peptide identification, classifier development and cross-study comparisons.
Validated urinary peptide-based diagnostic classifiers
A set of validated urine (and other biofluid) peptide-based classifiers for multiple clinical indications (including chronic kidney disease, graft rejection/GvHD, bladder and prostate cancer, cholangiocarcinoma and acute conditions such as severe COVID-19), developed and evaluated in multicentre cohorts.
Urine-based laboratory diagnostic assays (IVD channel)
Laboratory-implemented urine-based diagnostic tests marketed through diagnostic distribution channels to enable clinical detection and monitoring for selected indications.
Services
On-site laboratory proteomic and peptidomic analyses for research, diagnostics development and clinical study support using mass spectrometry-based workflows.
Data analysis pipelines, statistical evaluation and machine-learning frameworks for interpretation and integration of proteomic and multi-omics datasets.
Advisory and operational support for biomarker qualification, regulatory interactions and incorporation of proteomic classifiers into clinical trial design and patient stratification.
Computational integration of patient-derived multi-omics signatures with AI algorithms to nominate repurposing candidates, followed by in vitro and in vivo efficacy testing.
On-site laboratory proteomic and peptidomic analyses for research, diagnostics development and clinical study support using mass spectrometry-based workflows.
Data analysis pipelines, statistical evaluation and machine-learning frameworks for interpretation and integration of proteomic and multi-omics datasets.
Advisory and operational support for biomarker qualification, regulatory interactions and incorporation of proteomic classifiers into clinical trial design and patient stratification.
Computational integration of patient-derived multi-omics signatures with AI algorithms to nominate repurposing candidates, followed by in vitro and in vivo efficacy testing.
Expertise Areas
- Clinical proteomics and peptidomics
- Urinary biomarker discovery and validation
- Multi-omics integration and systems biology
- AI-driven drug repurposing and preclinical evaluation
Key Technologies
- Capillary electrophoresis–mass spectrometry (CE‑MS)
- MALDI and LC‑MS/MS mass spectrometry
- Targeted MRM protein quantification
- Urinary peptidomics/proteomics
News & Updates
The FDA has issued a support letter for a urinary peptide-based biomarker for early CKD detection.
Research on urinary peptidomics for risk assessment of type 2 diabetes.
Study on predicting prostate cancer recurrence using multiomic profiles.
The FDA has issued a support letter for a urinary peptide-based biomarker for early CKD detection.
Research on urinary peptidomics for risk assessment of type 2 diabetes.
Study on predicting prostate cancer recurrence using multiomic profiles.